Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder
Author:
Open Access
- 15 January 2018
- journal article
- review article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 9, 58-68
Abstract
Disorders related to parathyroid hormone (PTH) resistance and PTH signaling pathway impairment are historically classified under the term of pseudohypoparathyroidism (PHP). The disease was first described and named by Fuller Albright and colleagues in 1942. Albright hereditary osteodystrophy (AHO) is described as an associated clinical entity with PHP, characterized by brachydactyly, subcutaneous ossifications, round face, short stature and a stocky build. The classification of PHP is further divided into PHP-Ia, pseudo-PHP (pPHP), PHP-Ib, PHP-Ic and PHP-II according to the presence or absence of AHO, together with an in vivo response to exogenous PTH and the measurement of Gsα protein activity in peripheral erythrocyte membranes in vitro. However, PHP classification fails to differentiate all patients with different clinical and molecular findings for PHP subtypes and classification become more complicated with more recent molecular characterization and new forms having been identified. So far, new classifications have been established by the EuroPHP network to cover all disorders of the PTH receptor and its signaling pathway. Inactivating PTH/PTH-related protein signaling disorder (iPPSD) is the new name proposed for a group of these disorders and which can be further divided into subtypes - iPPSD1 to iPPSD6. These are termed, starting from PTH receptor inactivation mutation (Eiken and Blomstrand dysplasia) as iPPSD1, inactivating Gsα mutations (PHP-Ia, PHP-Ic and pPHP) as iPPSD2, loss of methylation of GNAS DMRs (PHP-Ib) as iPPSD3, PRKAR1A mutations (acrodysostosis type 1) as iPPSD4, PDE4D mutations (acrodysostosis type 2) as iPPSD5 and PDE3A mutations (autosomal dominant hypertension with brachydactyly) as iPPSD6. iPPSDx is reserved for unknown molecular defects and iPPSDn+1 for new molecular defects which are yet to be described. With these new classifications, the aim is to clarify the borders of each different subtype of disease and make the classification according to molecular pathology. The iPPSD group is designed to be expandable and new classifications will readily fit into it as necessary.Keywords
This publication has 90 references indexed in Scilit:
- Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasiaJournal of Clinical Investigation, 2013
- Exome Sequencing Identifies PDE4D Mutations in AcrodysostosisThe American Journal of Human Genetics, 2012
- Exome Sequencing Identifies PDE4D Mutations as Another Cause of AcrodysostosisThe American Journal of Human Genetics, 2012
- Heterotopic Ossifications in a Mouse Model of Albright Hereditary OsteodystrophyPLOS ONE, 2011
- Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type Ic defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsα-receptor interactionHuman Mutation, 2011
- An atypical case of hypomethylation at multiple imprinted lociEuropean Journal of Human Genetics, 2011
- Deletion and Point Mutations of PTHLH Cause Brachydactyly Type EThe American Journal of Human Genetics, 2010
- Central Nervous System Imprinting of the G Protein Gsα and Its Role in Metabolic RegulationCell Metabolism, 2009
- BrachydactylyOrphanet Journal of Rare Diseases, 2008
- The Alternative Stimulatory G Protein α-Subunit XLαs Is a Critical Regulator of Energy and Glucose Metabolism and Sympathetic Nerve Activity in Adult MiceJournal of Biological Chemistry, 2006